Acne Vulgaris Clinical Trial
Official title:
Prospective Double Blinded Randomized Assessment of the Effects of Silk Pillowcases on Acne Prone Skin
The purpose of this study is to determine the effects of using silk pillowcases in mild to moderate non-cystic acne prone skin in comparison to cotton pillowcases.
Status | Not yet recruiting |
Enrollment | 48 |
Est. completion date | November 10, 2023 |
Est. primary completion date | November 10, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 45 Years |
Eligibility | Inclusion Criteria: - Males and females between the ages of 15-45 years of age - The presence of mild to moderate acne vulgaris based on investigator global assessment - Presence of at least 5 inflammatory lesions and at least 5 non-inflammatory lesions Exclusion Criteria: - The presence of severe acne as noted by investigator global assessment. - Those who are unwilling to discontinue systemic antibiotics and benzoyl peroxide for 4 weeks meet the washout criteria prior to enrolling. - Those who are unwilling to keep their facial regimen consistent throughout the study, and for 1 month prior to enrolling. - Individuals who are unwilling to wash pillowcase every week using provided detergent. - Use of isotretinoin within the three months prior to enrolment - Individuals who primarily sleep on their back - Current tobacco smoker or a tobacco smoking history of greater than 10 pack year - Individuals on oral contraceptive pills or progesterone or estrogen containing therapies. - Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study - Individuals with known allergy or sensitivity to Mulberry Silk or Cotton Fibers in fabric |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Integrative Skin Science and Research |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acne Lesion Counts: Inflammatory Lesions | The inflammatory lesion counts will be counted and compared against baseline | 8 weeks | |
Primary | Acne Lesion Counts: Non-Inflammatory Lesions | The non-inflammatory lesion counts will be counted and compared against baseline | 8 weeks | |
Primary | Facial Erythema Intensity Score | Facial erythema will be measured as the erythema intensity score as measured by the image analysis system (BTBP 3D Pro) | 8 Weeks | |
Secondary | Transepidermal water loss | Change in Facial Trans-epidermal Water Loss, measured with vapometer | 8 Weeks | |
Secondary | Sebum Excretion Rate | Shift in the facial sebum excretion rate, measured with sebumeter | 8 weeks | |
Secondary | Skin Microbiome, relative abundance of C. acnes | Changes in skin microbiome relative abundance of C. acnes will be assessed with swab based collections of the facial skin microbiome | 8 Weeks | |
Secondary | Skin Hydration | Skin Hydration measured with MoistureMeter | 8 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 |